Janux Therapeutics (JANX) Non-Current Assets (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Non-Current Assets data on file, last reported at $26.2 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $26.2 million, down 4.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $105.2 million (down 7.28% YoY), and the FY2025 annual result was $25.7 million, down 7.8% from the prior year.
• Non-Current Assets grew to $26.2 million in Q1 2026 per JANX's latest filing, from $25.7 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $32.2 million in Q2 2023 and troughed at $3.9 million in Q1 2022.
• A 5-year average of $27.6 million and a median of $28.7 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2024: Non-Current Assets surged 12597.67% in 2022, then slipped 10.64% in 2024.
• A 5-year view of Non-Current Assets shows it stood at $31.6 million in 2022, then slipped by 1.28% to $31.2 million in 2023, then declined by 10.64% to $27.8 million in 2024, then slipped by 7.8% to $25.7 million in 2025, then increased by 1.94% to $26.2 million in 2026.
• Business Quant data shows JANX's Non-Current Assets at $26.2 million in Q1 2026, $25.7 million in Q4 2025, and $26.7 million in Q3 2025.